Sha Cheng

Ms. Sha Cheng


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2026 in Molecular Diversity
Verified
Journal Article
Closed access
PDF file
WTWei Tu
Wei Tu
NZNingning Zan
Ningning Zan
XLXinyu Liu
Xinyu Liu
GYGang Yu
Gang Yu
XZXiaoping Zeng
Xiaoping Zeng
GXGuangcan Xu
Guangcan Xu

Verified
Journal Article
Open access
PDF file
YJYu Jia
Yu Jia
GYGang Yu
Gang Yu
SCSha Cheng
Sha Cheng
LHLiangliang Hu
Liangliang Hu
NZNingning Zan
Ningning Zan
HLHeng Luo
Heng Luo
WRN helicases play a key role in DNA replication, repair, and other processes in a variety of tumors. It has become one of the hot targets of genotoxic drugs, but the effect and mechanism of targeting WRN against prostate cancer is still unclear. In our previous study, we found a quinazoline compound kzl052, which has a WRN-dependent inhibitory effect on prostate cancer cells, but its molecular mechanism needs to be further explored. In this study, kzl052 significantly inhibited the growth of PC3 (IC50 = 0.39 ± 0.01 μM) and LNCaP (IC50 = 0.11 ± 0.01 μM) cells in vitro and showed a good inhibition effect on PCa in vivo. It inhibits PC3 cell growth by binding to WRN proteins and affecting its non-enzymatic function. Then the mechanism of kzl052 against prostate cancer progression was revealed to be by regulating the stability of DNA replication forks and the RB pathway. This study will provide a theoretical basis and treatment strategy for targeting WRN helicase in the treatment of prostate cancer.

13 October 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
TYTing Ye
Ting Ye
JLJia-Hui Li
Jia-Hui Li
QXQin-Qin Xiong
Qin-Qin Xiong
CJCHEN ming juan
CHEN ming juan
SCSha Cheng
Sha Cheng
HLHeng Luo
Heng Luo
Background/Objectives: Hyperlipidemia is a prevalent metabolic disorder that increases cardiovascular disease risk and is associated with lipid accumulation, inflammation, and oxidative stress. Small-leaved Kuding tea (SLKT) has multiple health benefits, but its lipid-lowering mechanisms remain unclear. This study evaluated the therapeutic effects of different SLKT fractions on hyperlipidemia and investigated their modulation of the fatty acid degradation pathway. Methods: A hyperlipidemia mouse model was established using a high-fat diet for 8 weeks. Sixty successfully modeled mice were randomly divided into six groups: model control, anhydrous ethanol fraction (SLK-AE), ethyl acetate fraction (SLK-EA), n-butanol fraction (SLK-NA), water-soluble fraction (SLK-WA), and simvastatin (positive control). Mice received daily gavage for 8 weeks. Serum biochemical indices, inflammatory factors, hepatic oxidative stress markers, and liver histopathology were assessed. Protein expression levels of ACADM, EHHADH, and HADHB in the liver were detected by Western blot. Results: SLKT fractions significantly reduced body weight, fat mass, serum TC, TG, LDL-C, Glu, NEFA, ALT, AST, TNF-α, IL-1β, IL-6, and LPS, while increasing HDL-C (p < 0.05). Hepatic TC, TG, ALT, AST, and MDA decreased, and SOD increased (p < 0.05). Histological staining revealed markedly reduced lipid droplets in hepatocytes. Furthermore, SLKT significantly upregulated hepatic protein expression of ACADM, EHHADH, and HADHB, key enzymes in fatty acid β-oxidation (p < 0.05). Conclusions: SLKT effectively ameliorates hyperlipidemia by improving lipid profiles, reducing serum biomarkers of liver injury and pro-inflammatory cytokines, and upregulating key fatty acid degradation enzymes. These findings support SLKT as a potential natural therapeutic agent for hyperlipidemia and associated metabolic disorders.